Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tripadvisor Inc TRIP

TripAdvisor, Inc. is an online travel company. The Company leverage its brands, technology, and capabilities to connect its global audience with partners through content, travel guidance, and two-sided marketplaces for experiences, accommodations, restaurants, and other travel categories. The Company operates through three segments: Brand Tripadvisor, Viator, and TheFork. Its Brand Tripadvisor segment is engaged in providing an online global platform for travelers to discover, generate, and share authentic user-generated content (UGC) in the form of ratings and reviews for destinations, points-of-interest (POIs), experiences, accommodations, restaurants, and cruises. The Viator segment offers travelers a comprehensive online marketplace that provides access to over 350,000 experiences and more than 55,000 experience operators. The Fork segment offers an online marketplace that enables diners to discover and book online reservations at approximately 55,000 restaurants in 11 countries.


NDAQ:TRIP - Post by User

Post by Axell1818on Nov 02, 2020 5:22am
83 Views
Post# 31821547

Breakthrough therapy status

Breakthrough therapy status In 2018, the Food and Drug Administration first granted Compass Pathways a breakthrough therapy status, which accelerates the clinical study process, to study psilocybin particularly for parents struggling with Major Depressive Disorder. Since then the FDA has embraced the drug, granting similar designations to Compass and other large companies such as pharmaceutical giant Johnson & Johnson, but also smaller competitors such as Mind Medicine and Numinus Wellness.
<< Previous
Bullboard Posts
Next >>